Last reviewed · How we verify
DC-806
DC-806 is an anti-inflammatory monoclonal antibody targeting the IL-17 receptor.
DC-806 is an anti-inflammatory monoclonal antibody targeting the IL-17 receptor. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | DC-806 |
|---|---|
| Also known as | S011806, LY4100504 |
| Sponsor | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company |
| Drug class | IL-17 receptor antagonist |
| Target | IL-17 receptor |
| Modality | Small molecule |
| Therapeutic area | Inflammatory diseases |
| Phase | Phase 2 |
Mechanism of action
It works by binding to the IL-17 receptor, preventing IL-17 from interacting with its receptor and thereby reducing inflammation. This mechanism is thought to be beneficial in treating various inflammatory diseases.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
- Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants (PHASE1)
- A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis (PHASE2)
- A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis (PHASE1)
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants (PHASE1)
- A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DC-806 CI brief — competitive landscape report
- DC-806 updates RSS · CI watch RSS
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company portfolio CI